Clinical value of serum IgG4 subclass levels in patients with idiopathic retroperitoneal fibrosis

Pelkmans, L.G., Vermeer, E., Hendriksz, T.R., Bommel, E.F.H. van

Voorzitter(s): dr. P.M. Netten, ‘s-Hertogenbosch & dr. L.J.M. Reichert, Arnhem

Locatie(s): Auditorium 1

Categorie(ën):

test : In patients with idiopathic retroperitoneal fibrosis (iRPF), inflammation and fibrosis may be a manifestation of IgG4-related disease. As such, serum IgG4 levels may be of value as parameter of IgG4-related inflammation and in predicting treatment response.

Design: Prospective, observational study of 29 consecutive iRPF patients who were seen at our tertiary care referral centre from September 2010 through November 2013.

Measurements: Clinical, laboratory and radiological investigation was performed at presentation and at repeated follow-up. All but 2 patients were treated with tamoxifen. Treatment success was defined as such satisfactory clinical, laboratory and radiological response to tamoxifen during follow-up that there was no need to alter therapy. Treatment outcome analysis included patients who had at least 4 months of follow-up and who underwent at least the first CT scan follow-up. Second-line treatment consisted of corticosteroids, either alone or combined with other immunosuppressants.

Results: Overall, 13 patients (44.8%) had IgG4 levels above the normal range of 1.4 g/L. In patients with elevated IgG4 levels, locoregional lymphadenopathy (53.8% vs. 18.8%; P <0.01) and to lesser extent atypical mass localisation (30.7% vs. 6.3%; P=0.14) was observed more frequently compared to that in patients with normal range levels. Fibrotic mass thickness did not differ between patients with normal range or elevated IgG4 levels (median 28.0 [IQR 21.5-43.5] mm vs. 34.5 [IQR 16.5-50.3] mm; P=0.72). Males tended to have higher IgG4 levels compared to females (1.66 [0.7-4.1] g/L vs. 0.53 [0.4-1.3] g/L; P=0.09). Eleven of 24 patients (45.8%) who received tamoxifen eventually switched to second-line treatment. Success rate in tamoxifen-treated patients with normal range or elevated baseline IgG4 levels did not differ. However, non-responders to tamoxifen had higher baseline IgG4 levels compared to patients who responded satisfactorily to tamoxifen (1.31 g/L [0.7-7.3] g/L vs. 0.64 [0.3-1.7] g/L, P=0.05). All patients (100%) who had treatment failure were men, compared to 57% of patients with treatment success (P=0.02). In patients who had treatment failure with tamoxifen, IgG4 levels did not decrease until after switch to second-line treatment (∆IgG4 0.55 [0.1-2.5] before switch vs. 1.86 [0.6-7.2] after switch, P=0.01). Eleven of 13 patients had success of second-line therapy.

Conclusions: iRPF patients with elevated IgG4 levels may present more often with atypical mass localisation and particularly locoregional lymphadenopathy. Non-responders to tamoxifen had higher IgG4 levels than responders. Females seem to respond better to tamoxifen therapy, which might be explained by their lower IgG4 levels.

 

Sluiten  Toegevoegd aan Mijn programma.
Sluiten  Verwijderd uit Mijn programma.

loading